A Phase 1/2 Ascending Dose Study to Evaluate | Clinical Research Studies Listing

Recruiting

99 years or below

All

Phase 2

4 participants needed

1 Location

Brief description of study

Evaluate the safety, tolerability, and immunogenicity of 3 dose levels of PR006A administered via sub-occipital injection into the cisterna magna and Quantify PGRN levels in blood and CSF. Please refer to section 2 of the attached protocol. Please refer to section 2 of the attached protocol.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: 99 years or below
Gender: All

Updated on 09 Feb 2022. Study ID: 844811

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of PR006A in Patients with Fronto-Temporal Dementia with Progranulin Mutations (FTD-GRN)

Brief description of study

Eligibility of study

Find a site

Interested in the study